RxDoctor Payments Data

George Chow, MD

Neurology · Tarzana, CANPI 1932122413

Payments from drug & device makers

$16,248in general payments, 2019–2025

Across 817 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Biogen$981
  • Teva Pharmaceuticals USA, Inc.$932
  • Amgen$733
  • SK Life Science, Inc.$682
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$15,94398%
  • Education$3052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)91$2,059
Novartis77$1,269
Biogen52$981
Teva Pharmaceuticals USA, Inc.50$932
Amgen(2 entities)45$733
SK Life Science, Inc.33$682
UCB, Inc.21$614
AstraZeneca(2 entities)20$536
Acadia Pharmaceuticals Inc30$530
Kyowa Kirin, Inc.21$488
Eisai Inc.21$417
Pfizer24$393
Otsuka America Pharmaceutical, Inc.18$366
MDD US Operations, LLC25$355
Sunovion Pharmaceuticals Inc.17$328
Lilly USA, LLC13$294
Genentech USA, Inc.11$293
Biohaven Pharmaceuticals, Inc.22$267
Acorda Therapeutics, Inc12$266
EMD Serono, Inc.12$264
Argenx US, Inc.10$253
Bristol Myers Squibb11$250
Alnylam Pharmaceuticals Inc.10$217
Amneal Pharmaceuticals LLC11$215
Neurocrine Biosciences, Inc.8$208
Lundbeck LLC9$204
Adamas Pharmaceuticals, Inc.11$200
Tanabe Pharma America, Inc.8$176
Biohaven Pharmaceutical Holding Company Ltd.9$161
Banner Life Sciences, LLC7$139
Assertio Therapeutics, Inc.7$137
Takeda Pharmaceuticals U.S.A., Inc.6$126
Sumitomo Pharma America, Inc.6$114
Johnson & Johnson5$113
Nevro Corp.4$108
Zyla Life Sciences, Inc.11$104
Abbott6$102
Merz Pharmaceuticals, LLC3$98
Neurelis, Inc.5$94
Arbor Pharmaceuticals, Inc.5$86
Sanofi3$83
Bausch Health US, LLC3$68
Axsome Therapeutics, Inc.3$66
Forte Bio-pharma LLC3$66
Merz North America, Inc.3$61
ANI Pharmaceuticals, Inc.2$61
Azurity Pharmaceuticals, Inc.3$51
Jazz Pharmaceuticals Inc.2$51
Catalyst Pharmaceuticals, Inc.2$43
Avanir Pharmaceuticals, Inc.2$34
Vanda Pharmaceuticals Inc.2$32
Collegium Pharmaceutical, Inc.2$30
Cycle Pharmaceuticals Inc1$29
Cadwell Industries, Inc1$28
TG Therapeutics, Inc.1$27
Grifols USA, LLC1$26
E.r. Squibb & Sons, L.L.C.1$24
Octapharma USA, Inc.1$24
Tonix Medicines, Inc.1$23
Paratek Pharmaceuticals, Inc.1$22

How this compares

$16,248 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$75,516
Medicare patients
209
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NourianzIstradefylline13$46,567
QuliptaAtogepant18$22,892
Aimovig AutoinjectorErenumab-Aooe16$17,044
Nurtec OdtRimegepant Sulfate13$15,304
Ajovy AutoinjectorFremanezumab-Vfrm11$10,122
Memantine Hcl108$6,373
LyricaPregabalin14$4,664
Gabapentin148$3,718
Carbidopa-LevodopaCarbidopa/Levodopa62$2,560
Duloxetine Hcl51$2,428
Levetiracetam53$2,163
AmantadineAmantadine Hcl29$1,601
Pregabalin25$889
Escitalopram Oxalate39$709
Trazodone Hcl39$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kyowa Kirin, Inc.Nourianz$488$46,56713 claims
AbbVieQulipta$2,059$22,89218 claims
PfizerNurtec Odt, Lyrica$393$19,96927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →